Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients (Q40651201)

22 September 2017

0 references

Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients (English)

1 reference

22 September 2017

0 references

4

M Stumvoll

1 reference

22 September 2017

G McInnes

1

1 reference

22 September 2017

M Evans

2

1 reference

22 September 2017

S Del Prato

3

1 reference

22 September 2017

A Schweizer

5

1 reference

22 September 2017

V Lukashevich

6

1 reference

22 September 2017

Q Shao

7

1 reference

22 September 2017

W Kothny

8

1 reference

22 September 2017

7 August 2015

1 reference

Diabetes, Obesity and Metabolism

22 September 2017

1 reference

22 September 2017

17

1 reference

22 September 2017

1085-1092

1 reference

22 September 2017

11

1 reference

Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005.

22 September 2017

1 reference

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

21 January 2018

1 reference

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monother

21 January 2018

1 reference

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population

21 January 2018

1 reference

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

21 January 2018

1 reference

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

21 January 2018

1 reference

Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study.

21 January 2018

1 reference

Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia*.

21 January 2018

1 reference

Characterization of the influence of vildagliptin on model-assessed -cell function in patients with type 2 diabetes and mild hyperglycemia.

21 January 2018

1 reference

Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia

21 January 2018

1 reference

Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin

21 January 2018

1 reference

Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes

21 January 2018

1 reference

Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial

21 January 2018

1 reference

Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.

21 January 2018

1 reference

Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus

21 January 2018

1 reference

Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.

21 January 2018

1 reference

Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial

21 January 2018

1 reference

Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes

21 January 2018

1 reference

Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial.

21 January 2018

1 reference

Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus

21 January 2018

1 reference

Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study

21 January 2018

1 reference

Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study.

21 January 2018

1 reference

Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.

21 January 2018

1 reference

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

21 January 2018

1 reference

Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study

21 January 2018

1 reference

A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study

21 January 2018

1 reference

Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.

21 January 2018

1 reference

Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy

21 January 2018

1 reference

Effect of vildagliptin as add-on therapy to a low-dose metformin

21 January 2018

1 reference

Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus

21 January 2018

1 reference

Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.

21 January 2018

1 reference

Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus

21 January 2018

1 reference

Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.

21 January 2018

1 reference

Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.

21 January 2018

1 reference

Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea

21 January 2018

1 reference

Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus

21 January 2018

1 reference

Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus.

21 January 2018

1 reference

Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea

21 January 2018

1 reference

Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes

21 January 2018

1 reference

Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus

21 January 2018

1 reference

Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial

21 January 2018

1 reference

Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials

21 January 2018

1 reference

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

21 January 2018

1 reference

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

21 January 2018

1 reference

Sitagliptin pretreatment in diabetes patients presenting with acute coronary syndrome: results from the Acute Coronary Syndrome Israeli Survey (ACSIS).

21 January 2018

1 reference

Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study

21 January 2018

1 reference

Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial

21 January 2018

1 reference

Incretin-based drugs and the risk of congestive heart failure.

21 January 2018

1 reference

Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants

21 January 2018

1 reference

How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review

21 January 2018

1 reference

Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/DOM.12548

1 reference

22 September 2017

1 reference